DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia

Information source: Federal Neuro-Psychiatric Hospital, Yaba
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Acute Polymorphic Psychotic Disorder With Symptoms of Schizophrenia

Intervention: Jobelyn (Dietary Supplement); Haloperidol (Drug)

Phase: Phase 1/Phase 2

Status: Not yet recruiting

Sponsored by: Federal Neuro-Psychiatric Hospital, Yaba

Official(s) and/or principal investigator(s):
Moses Ojo, M.D., Principal Investigator, Affiliation: NPHY

Overall contact:
Adefemi Adeoye, M.D., Phone: +2348034752025, Email: phemmy_aa@yahoo.com


Sorghum bicolor is a naturally growing plant which has been of health benefit to the people of West Africa who traditionally prepare its leaf for various nutritional and health reasons. Its anti-inflammatory and haematocrit boosting properties have been well documented though the precise mechanism of action is still largely unknown. Its use has recently been extended to the field of mental health where findings in animal study suggest it could be of help in relieve of psychosis. The need for this study is therefore aimed at investigating the effect of this drug in patients with schizophrenia which is the prototypical psychotic disorder.

Clinical Details

Official title: Phase 2 Study of the Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia.

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Primary outcome: The primary outcome will be the changes in psychotic symptoms

Secondary outcome: Patient's general health and social functioning

Detailed description: Schizophrenia is a major psychiatric disorder with a chronic and debilitating course. It is the archetypal psychotic disorder with a prevalence of about 1% worldwide. The treatment of this psychotic disorder has evolved over the years after the discovery of Chlorpromazine. Despite the availability of several treatment options in practice, research into the possibility of creating a drug breakthrough continues. Sorghum bicolor, a naturally growing plant rich in several phytochemical including proanthocyanidins, anthocyanidins, apigenin, proapigeninidin, apigeninidin, luteolin, naringenins, flavonoids, and polyphenols (Omogbiya et al 2012) and prepared as a capsule called Jobelyn. This plant has been found to be of health benefit to the people of West Africa who traditionally prepare its leaf for various nutritional and health reasons. The anti-inflammatory and haematocrit boosting properties have been well documented and utilized though the precise mechanism of action is still not entirely known (Benson et al. 2013). Its usefulness in neuropsychiatric conditions has recently been explored albeit through animal studies. In animals, Jobelyn has been suggested to have anti-amnestic property which has been suggested to be related to its antioxidant activity (Umukoro et al. 2013a). Other studies also suggested that Jobelyn has an anti-aggressive effect (Umukoro et al. 2012) and antidepressant like property probably related to its stimulation of serotonergic pathways (Umukoro et al. 2013b). Jobelyn has also been suggested to exhibit anti-psychotic-like activity with the benefit of lacking extra-pyramidal side effect risks and therefore being postulated to be of possible benefit in the symptomatic relief of psychosis (Omogbiya et al. 2012). There is however limited information in terms of the suggested neuropsychiatric conditions especially in humans despite the recognized safety profile consequent upon its use as haematocrit boosting agent. This study therefore aims at exploring the usefulness of Jobelyn in the treatment of patients with Schizophrenia as an adjunct to standard treatment.


Minimum age: N/A. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria: Participants will be adults with current diagnosis of schizophrenia (meeting the ICD-10 criteria).

- Adults who are above 18 years of age and gave informed consent

- Currently meet the ICD-10 diagnosis of Schizophrenia and confirmed with MINI- PLUS

- Antipsychotic naive before recruitment into study or defaulted from treatment for at

least 6 months 'prior to contact with study

- Not on Jobelyn or Megafit currently or in the past 6months prior to contact with

study Exclusion Criteria:

- Having another current ICD-l0 diagnosis or a seizure disorder

- Serious or chronic physical illness

- Known severe drug allergies or hypersensitivity to Jobelyn, Megafit or Haloperidol

Locations and Contacts

Adefemi Adeoye, M.D., Phone: +2348034752025, Email: phemmy_aa@yahoo.com

Federal Neuro-Psychiatric Hospital Yaba - Lagos, Lagos 101212, Nigeria; Not yet recruiting
Adefemi A Adeoye, M.D., Sub-Investigator
I I Adeosun, M. D.., Sub-Investigator
O S Oluwaniyi, M.D., Sub-Investigator
J A Kajero, M.D., Sub-Investigator
T O Oduguwa, M.D., Sub-Investigator
T A Adewumi, M.D., Sub-Investigator
A A Adegbohun, M.D., Sub-Investigator
O H Famurewa, M.D., Sub-Investigator
Additional Information

Related publications:

Ayuba GI, Jensen GS, Benson KF, Okubena AM, Okubena O. Clinical efficacy of a West African sorghum bicolor-based traditional herbal preparation Jobelyn shows increased hemoglobin and CD4+ T-lymphocyte counts in HIV-positive patients. J Altern Complement Med. 2014 Jan;20(1):53-6. doi: 10.1089/acm.2013.0125. Epub 2013 Nov 27.

Geera B, Ojwang LO, Awika JM. New highly stable dimeric 3-deoxyanthocyanidin pigments from sorghum bicolor leaf sheath. J Food Sci. 2012 May;77(5):C566-72. doi: 10.1111/j.1750-3841.2012.02668.x. Epub 2012 Apr 10.

Benson KF, Beaman JL, Ou B, Okubena A, Okubena O, Jensen GS. West African Sorghum bicolor leaf sheaths have anti-inflammatory and immune-modulating properties in vitro. J Med Food. 2013 Mar;16(3):230-8. doi: 10.1089/jmf.2012.0214. Epub 2013 Jan 5.

Umukoro S, Adrian Omogbiya I, Taghogho Eduviere A. Evaluation of the Effect of Jobelyn® on Chemoconvulsants- Induced Seizure in Mice. BCN. 2013; 4 (2) 4 (2) :19-23 URL http://bcn.iums.ac.ir/browse.php?a_code=A-10-151&slc_lang=en&sid=1

Umukoro S, Ugbomah A, Aderibigbe A, Omogbiya A. Antioxidant Property of Jobelyn as the Possible Mechanism Underlying its Anti-amnesic Activity in Rodents. Basic Clin Neurosci. 2013 Winter;4(1):42-9.

Omogbiya IA, Umukoro S, Aderibigbe AO, Bakre AG. Jobelyn® pretreatment ameliorates symptoms of psychosis in experimental models. J Basic Clin Physiol Pharmacol. 2013;24(4):331-6. doi: 10.1515/jbcpp-2012-0073.

Umukoro S, Omogbiya IA, Eduviere TA. Effect of Jobelyn® on intruder- and isolation-induced aggressive behavior in mice. J Basic Clin Physiol Pharmacol. 2013;24(4):263-9. doi: 10.1515/jbcpp-2012-0069.

Toxicological Profiles of Commercial Herbal Preparation, Jobelyn® nternational Journal of Health Research, December 2009; 2(4): 369-374 © Poracom Academic Publishers. All rights reserved. Available at http://www.ijhr.org

The influence of African Herbal Formula on the haematological parameters of trypanosome infected rats VI Okochi, J Okpuzor, MO Okubena, AK Awoyemi African Journal of Biotechnology Vol.2(9) 2003: 312-316

Response of Trypanosoma brucei brucei-induced anaemia to a commercial herbal preparation ........... 4 African Journal of Biotechnology Vol. 2 (9), pp. 307‐311, September 2003

Thermal stability of 3-deoxyanthocyanidin pigments Liyi Yang , Linda Dykes , Joseph M. Awika Journal of Food Chemistry http://dx.doi.org/10.1016/j.foodchem.2014.03.105

Starting date: September 2014
Last updated: September 11, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017